BCMA-Directed Bispecific Antibodies in Early Relapse Multiple Myeloma

EP. 1: Defining Early Relapse and Treatment Selection in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

March 31st 2026

EP. 2: Unmet Needs in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

March 31st 2026

EP. 3: Role of Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 8th 2026

EP. 4: Interpreting MajesTEC-3 Efficacy in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 8th 2026

EP. 5: Subgroup Insights in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 15th 2026

EP. 6: Safety Considerations for Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 15th 2026

EP. 7: Managing Toxicities of Bispecific Antibodies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 22nd 2026

EP. 8: Mechanistic Rationale and Combination Strategies in Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 22nd 2026

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

EP. 9: Discussing Proper Utilization of BCMA Bispecifics in Early Relapse Multiple Myeloma

ByONCOLOGY Staff

April 24th 2026

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

EP. 10: Positioning Bispecific Therapy in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 29th 2026

EP. 11: Case-Based Sequencing Decisions in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

April 29th 2026

EP. 12: Sequencing CAR-T and Bispecifics in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 6th 2026

EP. 13: Risk Stratification and Shared Decision-Making in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 6th 2026

EP. 14: Managing Comorbid Patients in Early Relapse Multiple Myeloma

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 13th 2026

EP. 15: Key Takeaways for Early Relapse Multiple Myeloma Management

ByLuciano Costa, MD ,Muhamed Baljevic, MD,Carol Ann Huff, MD

May 13th 2026

Trending on CancerNetwork

Closing the HCC Surveillance Gap in MASLD Without Cirrhosis

Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC

Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care

Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis

Building Systems to Catch Liver and Other Cancers in Patients With MASLD